I don't see material upside or downside (for Boston Scientific shares) for the next 12 months.

238

I would venture that we are now outside of gentlemanly territory.

195

While it could be a knock-out blow, at what point are we overpaying? I think we could be getting close to that point based on the cardiac rhythm business.

176

While Johnson & Johnson has the clear technology lead, the risk they run is in setting the price. If the price is favorable, doctors will reward them when new products come to market.

166

If the deals went to shareholders today, we believe Boston Scientific would prevail.

165

It's probably the biggest thing that happened in the medical devices [industry] in the last 10 years.

135

I think a lot of folks had not expected them to be back this quickly.

130

You can't just sit back on your laurels. You have to constantly innovate.

94

[MacMillan] has big shoes to fill and he's inheriting a legacy of 20% earnings growth.

85